A Community Pharmacist-led Intervention to Improve Screening of Sleep Apnea in Primary Care

Overview

The purpose of this study is to evaluate the feasibility and the effectiveness of sleep apnea screening program for patients at risk in community pharmacies.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Screening
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2012

Detailed Description

Background: The sleep apnea syndrome (SAS) is a common disease but unknown. According to epidemiological studies, approximately 5% to 10% of the general population is living with SAS. Untreated sleep apnea has an important individual impact: it is accompanied by sleep disturbances and vigilance and frequent co-morbidities such as hypertension, diabetes or other cardiovascular diseases. Also, it has a cost to the community due to significant traffic accidents and work accidents more frequent in this population and weight for health insurance for cardiovascular diseases. However, its screening and its management remain largely insufficient. The report of the Ministry of Health in 2006 estimated that only 15% of subjects with a SAS would be diagnosed. The Law "Hospital, Patients, Health and Territories" (HPST) in 2009 provides pharmacists with new responsibilities in the health screening, care coordination, or in therapeutic education (Article 38 of Law HPST). Objective: In this dual context, this study aims to assess the feasibility and effectiveness of an information campaign and screening of SAS in patients at risk in the community pharmacies. The investigators analyze whether the involvement of community pharmacists in the care pathway of a patient at risk is effective, that is to say if it improves the detection rate and diagnostic the disease in this population. Project Description: 400 patients at risk of SAS will be recruited by the participating pharmacists. Screening intervention consists in 2 validated questionnaires which evaluate SAS risk (Berlin Questionnaire, Epworth Sleepiness Scale). Pharmacist distributes also an information leaflet about SAS, and refers patient to general practitioner with questionnaires results. Patients are followed by the pharmacists for 6 months.

Interventions

  • Other: screening of sleep apnea
    • 2 validated screening questionnaires (Berlin questionnaire, Epworth scale)

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of patients referred by the general practitioner to sleep specialist for SAS diagnosis test
    • Time Frame: 6 months after the intervention of pharmacists.

Secondary Measures

  • Satisfaction of patients and pharmacists
    • Time Frame: 6 months after the intervention of pharmacist
  • Proportion of patients with sleep apnea
    • Time Frame: 6 months after the intervention of pharmacists

Participating in This Clinical Trial

Inclusion Criteria

  • Taking 1 or more anti-hypertension drugs – Overweight (BMI > 25) – Snoring – Signed informed consent Exclusion Criteria:

  • To have a sleep apnea treatment – Not to have a referent doctor – To have a long-term illness – Did not sign informed consent

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Institut National de la Santé Et de la Recherche Médicale, France
  • Collaborator
    • Centre National de la Recherche Scientifique, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nathalise Pelletier-Fleury, Principal Investigator, Institut National de la Santé Et de la Recherche Médicale, France
  • Overall Contact(s)
    • Nathalie Pelletier-Fleury, +33149583325, npfleury@vjf.cnrs.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.